Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice

N A Sher, S D Chaparas, L E Greenberg, S Bernard, N A Sher, S D Chaparas, L E Greenberg, S Bernard

Abstract

An immunosuppressed mouse model was devised to test the effects of immunopotentiators on the prevention of bacterial and fungal infections. The effects of BCG and Corynebacterium were tested against Staphylococcus aureus and Candida albicans infection. The effect of methanol-extraction residue (MER-BCG) was tested against S. aureus septicemia. CDF mice were given various doses of BCG, 1.0 mg of C. parvum, or 0.5 mg of MER intraperitoneally at varying intervals before injection of an intravenous bacterial challenge. Four days before challenge, 300 mg of cyclophosphamide per ml was given intraperitoneally. BCG (106 colony-forming units) reduced mortality due to S.aureus at pretreatment intervals of 3, 7, 14, and 28 days. Isonicotinic acid hydrazide treatment elimated the protective effect of the live BCG. C. parvum was as effective as BCG against S. aureus septicemia when given 3 days before infection, but lost most of its protective effect after that time. MER protected at doses as small as 0.25 mg when given 25 days prior to challenge. Both BCG and C. parvum exerted a protective effect against Candida albicans infection.

References

    1. Br J Cancer Suppl. 1973 Aug;1:262-5
    1. J Immunol. 1973 Jan;110(1):277-82
    1. Am J Dis Child. 1971 Oct;122(4):283-7
    1. J Exp Med. 1969 May 1;129(5):1079-107
    1. Bacteriol Rev. 1968 Jun;32(2):85-102
    1. J Natl Cancer Inst. 1970 Oct;45(4):677-80
    1. J Reticuloendothel Soc. 1970 Feb;7(2):280-93
    1. Nature. 1968 Jul 13;219(5150):197-8
    1. J Reticuloendothel Soc. 1964 Jan;1:77-96
    1. Infect Immun. 1970 Jun;1(6):583-6
    1. Nature. 1960 Jun 25;186:1060-1
    1. J Exp Med. 1964 Jan 1;119:53-70
    1. Acta Tuberc Pneumol Scand. 1962;42:167-72
    1. J Exp Med. 1957 Nov 1;106(5):703-17
    1. Natl Cancer Inst Monogr. 1972 Dec;35:157-71
    1. Nat New Biol. 1972 Feb 16;235(59):219-20
    1. Lancet. 1974 Jul 20;2(7873):128-31
    1. Semin Hematol. 1972 Apr;9(2):141-79
    1. Infect Immun. 1972 Oct;6(4):465-8
    1. N Engl J Med. 1973 Mar 8;288(10):477-83
    1. Infect Immun. 1973 Nov;8(5):736-42
    1. Infect Immun. 1974 May;9(5):863-9
    1. Br J Exp Pathol. 1974 Feb;55(1):38-46

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi